Alzheimer Society of Ireland welcomes US approval of drug that slows the progression of disease
The US Food & Drug Administration’s (FDA) decision to approve the Lecanemab antibody, which will be sold under the name Leqembi, has been welcomed by the Alzheimer Society of Ireland (ASI). Leqembi targets the brain’s harmful amyloid beta protein under their accelerated approval pathway, and data suggests that it may be able to halt the … Read more